What is the current stock price of The Aaron's Company, Inc. (AAN)?

As of the latest market data, The Aaron's Company, Inc. (AAN) is trading at $10.09. The stock has seen a gain of 1.00% today.

Does The Aaron's Company, Inc. (AAN) pay a dividend?

Based on current data, The Aaron's Company, Inc. does not have a confirmed active dividend policy.

What is the market cap of The Aaron's Company, Inc.?

The current market capitalization of The Aaron's Company, Inc. (AAN) is approximately unavailable.

AAN

The Aaron's Company, Inc.·Industrials

10.09

1.001%(+0.10)

Market Closed

Last Updated: — ET

52W L: $6.6252W H: $11.90

AAN NEWS

globenewswire.com

4d ago

Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting

Five abstracts accepted including Late-breaking Science oral and poster presentations of Phase 3 X-TOLE2 study results for azetukalner in focal onset seizures Poster presentations also include long-term efficacy and safety data from X-TOLE open-label extension study of azetukalner, as well as real-world data regarding the burden of titration and need for no-titration options in epilepsy VANCOUVER, British Columbia and BOSTON, MA, April 07, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced multiple presentations at the upcoming American Academy of Neurology (AAN) Annual Meeting, taking place April 18-22, 2026 in Chicago, Illinois. Five abstracts will be presented, including a Late-breaking Science oral and poster presentation of the topline Phase 3 X-TOLE2 study results for azetukalner in focal onset seizures (FOS), as well as a poster presentation of long-term 48-month azetukalner data from the X-TOLE open label extension study.

globenewswire.com

Mar 6

argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline

Positive results from Phase 3 ADAPT OCULUS study show VYVGART's potential as the first targeted treatment for patients living with ocular MG Additional data from ADAPT SERON – the largest study of patients with gMG who do not have detectable AChR-Ab – demonstrate VYVGART's efficacy and safety across subtypes New biomarker analysis, real-world evidence and post-hoc insights highlight VYVGART's expanding treatment approach in CIDP March 6, 2026, 7:00 AM CEST Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, will present data for VYVGART® (IV: efgartigimod alfa-fcab and SC or Hytrulo: efgartigimod alfa and hyaluronidase-qvfc) and pipeline candidates empasiprubart and adimanebart at the 2026 American Academy of Neurology (AAN) Annual Meeting in Chicago from April 18-22, 2026. “The data we will present at AAN, including new Phase 3 results in ocular myasthenia gravis, demonstrate our relentless efforts to deliver a targeted treatment option to as many patients living with MG as possible,” said Luc Truyen, M.D.

Company Profile

The Aaron's Company, Inc. provides lease-to-own and purchase solutions. The company engages in direct-to-consumer sales and lease ownership of furniture, appliances, electronics, computers, and accessories through company-operated and franchised stores in the United States and Canada, as well as its e-commerce platform. It also manufactures and supplies bedding and upholstered furniture. As of December 31, 2021, the company operated 1,074 stores and 236 independently owned franchised stores. The company was formerly known as Aaron's SpinCo, Inc. The Aaron's Company, Inc. was founded in 1955 and is headquartered in Atlanta, Georgia.

Sector

Industrials

Industry

Rental & Leasing Services

Employees

9,071

IPO Date

2020-11-25

Beta

1.42

Websitewww.aarons.com↗